Comment
doi: 10.1016/S2213-2600(21)00489-6.
Epub 2021 Nov 8.
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply
Affiliations
- PMID: 34762847
- DOI: 10.1016/S2213-2600(21)00489-6
Item in Clipboard
Comment
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply
Lancet Respir Med.
2022 Jan.
No abstract available
Conflict of interest statement
AM-G has attended advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and Teva; is a steering committee member for the AstraZeneca PONENTE study; has received speakers' fees from AstraZeneca, Novartis, Roche, and Teva; has participated in research with AstraZeneca, for which his institution has been remunerated; has attended international conferences with Teva; and has made consultancy agreements with AstraZeneca, Sanofi, and Vectura. JK and RK are full-time employees of and stockholders in AstraZeneca. MG is a steering committee member for the AstraZeneca PONENTE study and has received speakers' fees from AstraZeneca, Novartis, and Teva.
Comment in
-
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy.Lancet Respir Med. 2022 Jan;10(1):e7. doi: 10.1016/S2213-2600(21)00487-2. Epub 2021 Nov 8. Lancet Respir Med. 2022. PMID: 34762848 No abstract available.
Comment on
-
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4. Lancet Respir Med. 2022. PMID: 34619104
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
